SNDX, NUVB, AURA : 3 Russell 2000 Stocks Analysts Say Could Soar Over 200%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 11 2025
0mins
Should l Buy NUVB?
Source: TipRanks
Investor Focus on Small-Cap Stocks: Amid economic uncertainty, investors are turning to smaller companies with high growth potential, particularly those in the Russell 2000 Index, including Syndax Pharmaceuticals, Nuvation Bio, and Aura Biosciences, all of which are developing cancer treatments and have received Strong Buy ratings from analysts.
Promising Upside Potential: Each company has shown significant upside potential according to analyst projections, with Syndax expected to rise by 229%, Nuvation by 227%, and Aura by 230%, despite recent stock declines of 28%, 15%, and 20% respectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUVB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUVB
Wall Street analysts forecast NUVB stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.360
Low
8.00
Averages
11.38
High
18.00
Current: 4.360
Low
8.00
Averages
11.38
High
18.00
About NUVB
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuvation Bio Under Investigation for Potential Claims
- Financial Results Disclosure: On March 2, 2026, Nuvation Bio reported its Q4 and full-year 2025 financial results, revealing that approximately 75% of treatment discontinuations occurred among later-line patient populations, indicating challenges in attracting long-term patients that could impact future revenue trends.
- Treatment Discontinuation Issues: Management explained that later-line patients tend to discontinue therapy quickly and often do not receive treatment for multiple quarters, which may lead to weak short-term revenue growth, reflecting potential risks in the company's market promotion efforts.
- Sharp Stock Decline: Following the financial results announcement, Nuvation Bio's shares plummeted, raising investor concerns about the company's future profitability, which could lead to decreased investor confidence and affect the company's ability to raise funds.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Nuvation Bio complied with federal securities laws, encouraging investors who suffered losses from holding the company's stock to join the investigation, highlighting significant concerns regarding the company's compliance.
See More
Knoll Capital Increases Stake in Nuvation Bio by 473,591 Shares
- Share Increase: On February 17, 2026, Knoll Capital Management disclosed an increase of 473,591 shares in Nuvation Bio, valued at approximately $2.93 million, indicating confidence in the company's growth potential and future prospects.
- Holding Status: Following the purchase, Knoll Capital's total holdings in Nuvation Bio reached 1,498,591 shares, reflecting an increase of $7.88 million from the previous report, driven by both the additional purchase and stock price appreciation.
- Market Performance: As of February 17, 2026, Nuvation Bio's shares were priced at $4.25, representing a 130% increase over the past year, significantly outperforming the S&P 500's roughly 16% gain during the same period, showcasing its strong position in the biotech sector.
- Financial Condition: Nuvation Bio ended 2025 with $529.2 million in cash and marketable securities, and despite a net loss of $204.6 million for the year, its product revenue is gradually increasing, indicating potential for commercialization and market acceptance.
See More
NUVB Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: NUVB's 52-week low is $1.54 per share, while the high is $9.75, with the last trade at $4.26, indicating significant volatility in the stock over the past year, reflecting varying market perceptions.
- Market Trend Observation: The current price of $4.26 is 174% higher than the 52-week low but still 56.2% below the high, suggesting a rebound yet an overall performance that has not returned to peak levels, potentially affecting investor confidence.
- Technical Indicator Focus: NUVB's stock price has fallen below its 200-day moving average, typically viewed as a technical sell signal, which may lead to further selling pressure in the short term, impacting market sentiment.
- Investor Sentiment Assessment: Despite the current stock price being at a mid-level, the significant disparity between its high and low points necessitates cautious evaluation of market trends and potential risks by investors to formulate appropriate investment strategies.
See More
Nuvation Bio Reports Strong 2025 Financial Results Driven by Lung Cancer Therapy
- Significant Revenue Growth: Nuvation Bio reported fourth-quarter revenue of $41.9 million for 2025, a substantial increase from $5.7 million in the same quarter of 2024, indicating rapid adoption of its newly launched lung cancer therapy IBTROZI, which is expected to drive future revenue growth.
- Narrowed Net Loss: The company achieved a net loss of $36.6 million (or $0.11 per share) in Q4 2025, down from a net loss of $49.4 million (or $0.15 per share) in Q4 2024, reflecting effective cost control and revenue growth strategies.
- Surge in IBTROZI Adoption: IBTROZI saw 216 new patient starts in Q4 2025, bringing the total to 432, with adoption rates approximately six times higher than previous ROS1 inhibitor launches, demonstrating strong market demand and potential for the drug.
- Global Expansion Plans: Nuvation entered an exclusive licensing agreement with Eisai to expand IBTROZI's reach across Europe and other international markets, while also receiving a $25 million milestone payment from Nippon Kayaku, further strengthening the company's financial position.
See More
Ouster Inc Reports Strong Q4 Results, Shares Surge
- Strong Performance: Ouster Inc reported fourth-quarter revenue of $62.18 million, surpassing analyst expectations of $41.1 million, indicating robust market performance that is likely to boost investor confidence.
- Loss Improvement: The company reported a fourth-quarter loss of six cents per share, significantly better than the expected loss of 35 cents, demonstrating substantial progress in cost control and operational efficiency.
- Stock Price Surge: Ouster's shares jumped 13.8% to $23.04 in pre-market trading, reflecting a positive market reaction to its financial results, which may attract more investor interest.
- Optimistic Outlook: Ouster issued first-quarter sales guidance above estimates, signaling strong future prospects that could further drive stock price increases and enhance market confidence in its growth trajectory.
See More
Nuvation Bio Inc. Reports Strong Q4 2025 Earnings and Growth Prospects
- IBTROZI Market Performance: By the end of 2025, IBTROZI treated 432 new patients, with 216 starting in Q4, indicating rapid penetration in the ROS1-positive non-small cell lung cancer market, and its prescription rate is six times faster than previous ROS1 TKI launches, suggesting strong market demand and competitive advantage.
- Financial Performance: Total revenue for Q4 reached $41.9 million, with IBTROZI contributing $15.7 million in net U.S. product revenue, leading to a full-year total of $24.7 million, reflecting solid revenue growth, while cash reserves stood at $529.2 million, indicating no need for additional financing to achieve profitability.
- R&D Progress: The company initiated the pivotal Phase III SIGMA study for high-risk IDH1 mutant glioma and plans to file for European approval of IBTROZI in 2026, demonstrating strategic commitment to global market expansion and potential new revenue streams.
- Market Outlook: Management expressed optimism for patient growth in 2026, anticipating a shift in IBTROZI usage towards first-line patients, which will align revenue growth more closely with new patient starts, further solidifying its market position.
See More
Nuvation Bio Under Investigation for Potential Claims
- Financial Results Disclosure: On March 2, 2026, Nuvation Bio reported its Q4 and full-year 2025 financial results, revealing that approximately 75% of treatment discontinuations occurred among later-line patient populations, indicating challenges in attracting long-term patients that could impact future revenue trends.
- Treatment Discontinuation Issues: Management explained that later-line patients tend to discontinue therapy quickly and often do not receive treatment for multiple quarters, which may lead to weak short-term revenue growth, reflecting potential risks in the company's market promotion efforts.
- Sharp Stock Decline: Following the financial results announcement, Nuvation Bio's shares plummeted, raising investor concerns about the company's future profitability, which could lead to decreased investor confidence and affect the company's ability to raise funds.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Nuvation Bio complied with federal securities laws, encouraging investors who suffered losses from holding the company's stock to join the investigation, highlighting significant concerns regarding the company's compliance.
See More
Knoll Capital Increases Stake in Nuvation Bio by 473,591 Shares
- Share Increase: On February 17, 2026, Knoll Capital Management disclosed an increase of 473,591 shares in Nuvation Bio, valued at approximately $2.93 million, indicating confidence in the company's growth potential and future prospects.
- Holding Status: Following the purchase, Knoll Capital's total holdings in Nuvation Bio reached 1,498,591 shares, reflecting an increase of $7.88 million from the previous report, driven by both the additional purchase and stock price appreciation.
- Market Performance: As of February 17, 2026, Nuvation Bio's shares were priced at $4.25, representing a 130% increase over the past year, significantly outperforming the S&P 500's roughly 16% gain during the same period, showcasing its strong position in the biotech sector.
- Financial Condition: Nuvation Bio ended 2025 with $529.2 million in cash and marketable securities, and despite a net loss of $204.6 million for the year, its product revenue is gradually increasing, indicating potential for commercialization and market acceptance.
See More
NUVB Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: NUVB's 52-week low is $1.54 per share, while the high is $9.75, with the last trade at $4.26, indicating significant volatility in the stock over the past year, reflecting varying market perceptions.
- Market Trend Observation: The current price of $4.26 is 174% higher than the 52-week low but still 56.2% below the high, suggesting a rebound yet an overall performance that has not returned to peak levels, potentially affecting investor confidence.
- Technical Indicator Focus: NUVB's stock price has fallen below its 200-day moving average, typically viewed as a technical sell signal, which may lead to further selling pressure in the short term, impacting market sentiment.
- Investor Sentiment Assessment: Despite the current stock price being at a mid-level, the significant disparity between its high and low points necessitates cautious evaluation of market trends and potential risks by investors to formulate appropriate investment strategies.
See More
Nuvation Bio Reports Strong 2025 Financial Results Driven by Lung Cancer Therapy
- Significant Revenue Growth: Nuvation Bio reported fourth-quarter revenue of $41.9 million for 2025, a substantial increase from $5.7 million in the same quarter of 2024, indicating rapid adoption of its newly launched lung cancer therapy IBTROZI, which is expected to drive future revenue growth.
- Narrowed Net Loss: The company achieved a net loss of $36.6 million (or $0.11 per share) in Q4 2025, down from a net loss of $49.4 million (or $0.15 per share) in Q4 2024, reflecting effective cost control and revenue growth strategies.
- Surge in IBTROZI Adoption: IBTROZI saw 216 new patient starts in Q4 2025, bringing the total to 432, with adoption rates approximately six times higher than previous ROS1 inhibitor launches, demonstrating strong market demand and potential for the drug.
- Global Expansion Plans: Nuvation entered an exclusive licensing agreement with Eisai to expand IBTROZI's reach across Europe and other international markets, while also receiving a $25 million milestone payment from Nippon Kayaku, further strengthening the company's financial position.
See More
Ouster Inc Reports Strong Q4 Results, Shares Surge
- Strong Performance: Ouster Inc reported fourth-quarter revenue of $62.18 million, surpassing analyst expectations of $41.1 million, indicating robust market performance that is likely to boost investor confidence.
- Loss Improvement: The company reported a fourth-quarter loss of six cents per share, significantly better than the expected loss of 35 cents, demonstrating substantial progress in cost control and operational efficiency.
- Stock Price Surge: Ouster's shares jumped 13.8% to $23.04 in pre-market trading, reflecting a positive market reaction to its financial results, which may attract more investor interest.
- Optimistic Outlook: Ouster issued first-quarter sales guidance above estimates, signaling strong future prospects that could further drive stock price increases and enhance market confidence in its growth trajectory.
See More
Nuvation Bio Inc. Reports Strong Q4 2025 Earnings and Growth Prospects
- IBTROZI Market Performance: By the end of 2025, IBTROZI treated 432 new patients, with 216 starting in Q4, indicating rapid penetration in the ROS1-positive non-small cell lung cancer market, and its prescription rate is six times faster than previous ROS1 TKI launches, suggesting strong market demand and competitive advantage.
- Financial Performance: Total revenue for Q4 reached $41.9 million, with IBTROZI contributing $15.7 million in net U.S. product revenue, leading to a full-year total of $24.7 million, reflecting solid revenue growth, while cash reserves stood at $529.2 million, indicating no need for additional financing to achieve profitability.
- R&D Progress: The company initiated the pivotal Phase III SIGMA study for high-risk IDH1 mutant glioma and plans to file for European approval of IBTROZI in 2026, demonstrating strategic commitment to global market expansion and potential new revenue streams.
- Market Outlook: Management expressed optimism for patient growth in 2026, anticipating a shift in IBTROZI usage towards first-line patients, which will align revenue growth more closely with new patient starts, further solidifying its market position.
See More
